Eli Lilly & Co. LLY
$1251.61
+3.55%
at last close
Market Cap$1.08 trillion
P/E Ratio—
Div Yield0.55%
Volume3.75M
52-Week Range
$712.05$1292.65
Analyst Ratings
- Consensus
- Buy — 19 Buy · 1 Hold · 1 Sell (21 analysts)
- Avg. Price Target
- $1320.76 (+5.5% upside)
Key Stats
- Today's Range
- $1230.66 – $1275.88
- 50-Day Range
- $1113.29 – $1292.65
- 52-Week Range
- $712.05 – $1292.65
- Volume
- 3.75 million shs
- Average Volume
- 2.29 million shs
- Market Cap
- $1.08 trillion
- P/E Ratio
- —
- Dividend Yield
- 0.55%
Dividend
- Dividend Yield
- 0.55%
- Annual Dividend
- $6.92
- Payout Ratio
- —
- Ex-Dividend Date
- 2026-08-14
Short Interest
- Short Interest
- 1.29%
- Days to Cover
- 5.12
About Eli Lilly & Co.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Related Stocks
Compare head-to-head: LLY vs JNJ·LLY vs ABBV·LLY vs ABT·LLY vs PFE
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.